In November 2021, the FDA granted a fast track designation to bemcentinib in combination with a PD-1/PD-L1 agent in the treatment of patients with STK11-altered advanced or metastatic NSCLC without actionable mutations. Here, STK11 is linked to non-small cell lung carcinoma.